AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Business Wire
Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer Research? (AACR) 116th Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois, taking place April 25 to 30, 2025.Targeting prostate-specific membrane antigen (PSMA) with a CD3 TCE could provide an effective treatment option for metastatic castration-resistant prostate cancer (mCRPC). In its poster presentation at AACR, AbCellera demonstrated that its PSMA x CD3 TCEs show promising preclinical activity, including:Potent in vitro tumor-cell killing, with one molecule showing ~10x higher EC50 than benchmarkSustained in vitro activity across four rounds of serial T-cell killingPreclinical in vivo ef
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- We're Not Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn [Yahoo! Finance]Yahoo! Finance
- AbCellera and Bruker Reach Global Settlement of Patent LitigationBusiness Wire
- AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026Business Wire
- AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss [Yahoo! Finance]Yahoo! Finance
ABCL
Earnings
- 11/6/25 - Miss
ABCL
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 3
- 12/19/25 - Form 4
- ABCL's page on the SEC website